Stem Cell Clinic

Audio-Digest Foundation Announces the Release of Oncology Volume 04, Issue 22: What’s New in Breast Cancer?

By Stem Cell Medical Center

Glendale, CA (PRWEB) January 26, 2014

Audio-Digest Foundation Announces the Release of Oncology Volume 04, Issue 22: Whats New in Breast Cancer?

The goal of this program is to improve the management of breast cancer. After hearing and assimilating this program, the clinician will be better able to:

1. Recognize the role of cancer stem cells and their microenvironment in the development and recurrence of breast cancer. 2. List components of the stem cell compartment and microenvironment that promote the development of breast cancer. 3. Explain a proposed mechanism by which cancer stem cells may maintain their stemness. 4. Select patients most likely to benefit from prolonged tamoxifen therapy. 5. Weigh the benefits and risks of newer breast cancer therapies.

The original programs were presented by Issam Makhoul, MD, Assistant Professor, Division of Hematology/Oncology, Department of Internal Medicine, and University of Arkansas for Medical Sciences, College of Medicine, Little Rock.

Audio-Digest Foundation, the largest independent publisher of Continuing Medical Education in the world, records over 10,000 hours of lectures every year in anesthesiology, emergency medicine, family practice, gastroenterology, general surgery, internal medicine, neurology, obstetrics/gynecology, oncology, ophthalmology, orthopaedics, otolaryngology, pediatrics, psychology, and urology, by the leading medical researchers at the top laboratories, universities, and institutions.

Recent researchers have hailed from Harvard, Cedars-Sinai, Mayo Clinic, UCSF, The University of Chicago Pritzker School of Medicine, The University of Kansas Medical Center, The University of California, San Diego, The University of Wisconsin School of Medicine, The University of California, San Francisco, School of Medicine, Johns Hopkins University School of Medicine, and many others.

Out of these cutting-edge programs, Audio-Digest then chooses the most clinically relevant, edits them for clarity, and publishes them either every week or every two weeks.

In addition, Audio-Digest publishes subscription series in conjunction with leading medical societies: DiabetesInsight with The American Diabetes Association, ACCEL with The American College of Cardiology, Continuum Audio with The American Academy of Neurology, and Journal Watch Audio General Medicine with Massachusetts Medical Society.

For 60 years, the global medical community of doctors, nurses, physician assistants, and other medical professionals around the world has subscribed to Audio-Digest specialty series in order to remain current in their specialties as well as to maintain their Continuing Education requirements with the most cutting-edge, independent, and unbiased continuing medical education (CME).

Original post:
Audio-Digest Foundation Announces the Release of Oncology Volume 04, Issue 22: What’s New in Breast Cancer?

Stem-cell therapy restores faith for arthritic pets

By Stem Cell Treatment

ELLSWORTH Visitors to the Bellaire pet crisis center With a Little help From My Friends get an official welcome from Moka.

The Labrador retriever was found behind a Bellaire restaurant in 2011 and now serves as the centers mascot.

Peforming her duties has been increasingly difficult for the dog, who suffers from severe arthritis in her hips. So recently the center turned to Ellsworth veterinarian Christian Randall of North Country Veterinary Services, the first in northern Michigan to offer in-clinic adipose stem cell therapy.

The procedure uses a pets own blood and tissue to produce plasma-rich platelets and stem cells that proliferate growth in damaged areas.

Dormant stem cells are separated from adipose -- fat tissue -- and activated with an LED technology that uses three different wave lengths of light. Then the cells are injected directly into the affected area or administered intravenously to help promote regeneration. The result is a decrease in pain and lameness and increased range of motion.

Its using the bodys own repair cells to repair damage, said Trey Smith, director of laboratory services for MediVet America, which developed the technology Randall uses.

The therapy is the first treatment to help heal and slow the progression of osteoarthritis and degenerative joint disease rather than just cope with the symptoms, said Randall, who saw the results while studying at Virginia Equine Imaging and now plans to use it on equine as well as canine and feline patients.

It concentrates, speeds up and amplifies the bodys own healing power, he said.

Stem cell therapy has been around for a while, but in-clinic availability of the technology is new. Only a handful of veterinarians in Ann Arbor and Grand Rapids offer the services, said Randall, who charges $1,800 to treat a dog or cat. Repeat injections are possible with banked plasma-rich platelets and stem cells.

Before the one-day procedure, veterinarians had to send blood and tissue to an outside lab for processing, a more costly three-day procedure that requires an animal's return visit to the vet for injection.

Read more from the original source:
Stem-cell therapy restores faith for arthritic pets

Stem Cell Treatment in Miami Florida – Call Now 1 888 545 …

By Stem Cell Doctors

erectile dysfunction treatment, type 2 diabetes treatment, arthritis cure, cure for arthritis, therapy for autism, Vision loss therapy, hair loss treatment, preventing hair loss, Pumonary disease therapy, Kidney diseases

CellTherapyFlorida U.S. Program and PRP Therapy are now being applied towards painful, injured and inflammatory conditions facilitating healing of muscle, tendons, ligaments, articular and meniscal injuries.

Loss of Hair Your own stem cells from a small area of adipose (fat) tissue can be isolated and activated. Together with a PRP and growth factors from a small sample of blood, it can be locally injected into the scalp for male and female pattern hair loss treatment.

A single treatment of Stem Cells can be of a long-term benefit. Other therapies and drugs are an hours-to-days alternative!

The utilization of insulin in the conventional treatment of diabetes mellitus is only a "symptomatic" approach, and curing diabetes involves a great deal more.

Due to the fact most of the diseases that lead to loss of vision do so as a result of abnormal vasculature and/or nerve degeneration, the use of stem cells to stabilize or prevent visual loss holds great promise.

Autism is characterized by abnormalities in social interaction, impaired verbal and nonverbal communication, and repetitive, obsessive behavior.

Regenerative cellular therapy aims for the return of damaged lung(s) to a more functional state through the use of autologous adult stem cells. Promising results have been reported in patients with lung diseases receiving this type of regenerative therapy.

Chronic kidney disease means progressive loss of the kidney function that leads to end stage kidney disease (ESKD). End stage kidney disease is the complete or almost complete kidney function failure. This condition takes place when kidneys lose their ability to maintain the day to day level of function.

Read the original:
Stem Cell Treatment in Miami Florida - Call Now 1 888 545 ...

Clinical trial studies vaccine targeting cancer stem cells in brain cancers

By Stem Cell Medical Center

An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

Like normal stem cells, cancer stem cells have the ability to self-renew and generate new cells, but instead of producing healthy cells, they create cancer cells. In theory, if the cancer stem cells can be destroyed, a tumor may not be able to sustain itself, but if the cancer originators are not removed or destroyed, a tumor will continue to return despite the use of existing cancer-killing therapies.

The Phase I study, which will enroll about 45 patients and last two years, evaluates safety and dosing of a vaccine created individually for each participant and designed to boost the immune system's natural ability to protect the body against foreign invaders called antigens. The drug targets a protein, CD133, found on cancer stem cells of some brain tumors and other cancers.

Immune system cells called dendritic cells will be derived from each patient's blood, combined with commercially prepared glioblastoma proteins and grown in the laboratory before being injected under the skin as a vaccine weekly for four weeks and then once every two months, according to Jeremy Rudnick, MD, neuro-oncologist in the Cedars-Sinai Department of Neurosurgery and Department of Neurology, the study's principal investigator.

Dendritic cells are the immune system's most powerful antigen-presenting cells -- those responsible for helping the immune system recognize invaders. By being loaded with specific protein fragments of CD133, the dendritic cells become "trained" to recognize the antigen as a target and stimulate an immune response when they come in contact.

The cancer stem cell study is the latest evolution in Cedars-Sinai's history of dendritic cell vaccine research, which was introduced experimentally in patient trials in 1998.

Cedars-Sinai's brain cancer stem cell study is open to patients whose glioblastoma multiforme has returned following surgical removal. Potential participants will be screened for eligibility requirements and undergo evaluations and medical tests at regular intervals. The vaccine and study-related tests and follow-up care will be provided at no cost to patients. For more information, call 1-800-CEDARS-1 or contact Cherry Sanchez by phone at 310-423-8100 or email cherry.sanchez@cshs.org.

Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center.Note: Materials may be edited for content and length.

Visit link:
Clinical trial studies vaccine targeting cancer stem cells in brain cancers

stem cell therapy treatment for cerebral palsy sri lanka by dr alok sharma, mumbai, india – Video

By Uncategorized


stem cell therapy treatment for cerebral palsy sri lanka by dr alok sharma, mumbai, india
improvement seen in just 3 months after stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai, india. Stem Cell Therapy done date 4/10/201...

By: Neurogen Brain and Spine Institute

Go here to see the original:
stem cell therapy treatment for cerebral palsy sri lanka by dr alok sharma, mumbai, india - Video

stem cell therapy treatment for muscular dystrophy by dr alok sharma, mumbai, india – Video

By Uncategorized


stem cell therapy treatment for muscular dystrophy by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for muscular dystrophy by dr alok sharma, mumbai, india. Stem Cell Therapy done date 24/12/...

By: Neurogen Brain and Spine Institute

See the original post:
stem cell therapy treatment for muscular dystrophy by dr alok sharma, mumbai, india - Video

Cedars-Sinai clinical trial studies vaccine targeting cancer stem cells in brain cancers

By Stem Cell Medical Center

PUBLIC RELEASE DATE:

24-Jan-2014

Contact: Sandy Van sandy@prpacific.com 808-526-1708 Cedars-Sinai Medical Center

LOS ANGELES (Jan. 24, 2014) An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

Like normal stem cells, cancer stem cells have the ability to self-renew and generate new cells, but instead of producing healthy cells, they create cancer cells. In theory, if the cancer stem cells can be destroyed, a tumor may not be able to sustain itself, but if the cancer originators are not removed or destroyed, a tumor will continue to return despite the use of existing cancer-killing therapies.

The Phase I study, which will enroll about 45 patients and last two years, evaluates safety and dosing of a vaccine created individually for each participant and designed to boost the immune system's natural ability to protect the body against foreign invaders called antigens. The drug targets a protein, CD133, found on cancer stem cells of some brain tumors and other cancers.

Immune system cells called dendritic cells will be derived from each patient's blood, combined with commercially prepared glioblastoma proteins and grown in the laboratory before being injected under the skin as a vaccine weekly for four weeks and then once every two months, according to Jeremy Rudnick, MD, neuro-oncologist in the Cedars-Sinai Department of Neurosurgery and Department of Neurology, the study's principal investigator.

Dendritic cells are the immune system's most powerful antigen-presenting cells those responsible for helping the immune system recognize invaders. By being loaded with specific protein fragments of CD133, the dendritic cells become "trained" to recognize the antigen as a target and stimulate an immune response when they come in contact.

The cancer stem cell study is the latest evolution in Cedars-Sinai's history of dendritic cell vaccine research, which was introduced experimentally in patient trials in 1998.

Cedars-Sinai's brain cancer stem cell study is open to patients whose glioblastoma multiforme has returned following surgical removal. Potential participants will be screened for eligibility requirements and undergo evaluations and medical tests at regular intervals. The vaccine and study-related tests and follow-up care will be provided at no cost to patients. For more information, call 1-800-CEDARS-1 or contact Cherry Sanchez by phone at 310-423-8100 or email cherry.sanchez@cshs.org.

More here:
Cedars-Sinai clinical trial studies vaccine targeting cancer stem cells in brain cancers

Stem-cell company in crisis

By Stem Cell Treatment

PROFESSOR MIODRAG STOJKOVIC/SCIENCE PHOTO LIBRARY

Advanced Cell Technology is running the only US trials of embryonic-stem-cell therapies.

Advanced Cell Technology (ACT), a biotechnology company based in Marlborough, Massachusetts, has long flirted with fame and bankruptcy.

The company is running the only US Food and Drug Administration (FDA)-approved clinical trials of embryonic stem (ES)-cell therapies. Later this month, ACT plans to report preliminary results from three trials to test the safety of its treatment for two different forms of vision loss. If all goes well, it could be the first clinical demonstration of the safety and perhaps also the therapeutic potential of ES cells.

Yet a series of financial missteps could cost ACT the opportunity to see that potential become reality. On 22 January, the firm announced that its chief executive, Gary Rabin, was stepping down. The news came a month after ACT which had US$5.5 million in cash on-hand as of 30 September 2013 announced that it would pay $4 million to settle a Securities and Exchange Commission (SEC) charge alleging that the company had illegally sold billions of shares of stock.

Thats a big hit for any biotechnology company, says Gregory Bonfiglio, a venture capitalist with Proteus Venture Partners in Portola Valley, California. This is a very painful time for them.

ACT is accustomed to the pain: it has been running on fumes for years and has repeatedly skirted bankruptcy. The company announced this week that it aims to begin the next round of its clinical trials in the second half of 2014. But its last quarterly statement, which covered the period ending 30 September, revealed that the company had only enough funds to last into the second half of 2014. ACT spokesman David Schull says that the firm is exploring all financing options and plans to expand its clinical operations to accommodate the upcoming trials.

That financing may have to carry ACT through additional legal charges. The settlement with the Securities and Exchange Commission was just one of a string of cases ACT has handled over the past few years as it dealt with the legacy left by the fundraising schemes of its previous chief executive, William Caldwell. One such case is still pending, and the SEC has launched a separate investigation of Rabin for distributing stock without reporting it to the SEC in a timely fashion.

More recently, on 2 January, the Wisconsin Alumni Research Foundation (WARF) sued ACT for breach of contract. WARF, which handles patents and licensing for the University of Wisconsin, holds a number of key ES-cell patents, and ACT struck a licensing deal with the foundation in 2007. The case has been sealed, and lawyers representing WARF did not respond immediately to requests for comment.

ACT may soon have company in the clinic. The London Project to Cure Blindness has been developing an ES cellderived therapy to treat age-related macular degeneration, a leading form of vision loss in people aged 50 and older.

See more here:
Stem-cell company in crisis

→←